Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/Latest News/Breakthrough: Takeda’s QDENGA Approved in India Despite Prior Dengue
Breakthrough: Takeda's QDENGA Approved in India Despite Prior Dengue
Latest News

Breakthrough: Takeda’s QDENGA Approved in India Despite Prior Dengue

By adminitfy
July 20, 2026 2 Min Read

Takeda Biopharmaceuticals India announced on July 20, 2026 that India’s drug regulatory authority has granted market authorisation for QDENGA, its dengue vaccine, for people aged 4–60 years. The company said QDENGA is the first dengue vaccine approved in India that can be given regardless of prior dengue exposure, removing the need for pre-vaccination testing.

Dengue is a mosquito-borne viral disease that affects more than 125 countries and is a major public health threat. Takeda noted that India accounts for nearly one-third of the global dengue burden; reported cases in 2025 exceeded 113,000, though modelling suggests the true burden in India may be far higher, likely amounting to tens of millions of infections each year.

QDENGA is a tetravalent, live-attenuated vaccine formulated to protect against all four dengue virus serotypes. It is administered subcutaneously as a 0.5 mL dose in a two-dose schedule, with the second dose given three months after the first. The World Health Organization has recommended the vaccine for use in dengue-endemic settings and granted WHO prequalification to QDENGA a few years earlier.

Takeda said the Indian approval rests on data from its global clinical development programme, which included 19 Phase 1, 2 and 3 trials with more than 28,000 participants in both endemic and non-endemic regions. The pivotal Phase III TIDES (DEN-301) trial enrolled over 20,000 participants across eight countries and evaluated long-term safety and efficacy.

The approval is also supported by a Phase III trial conducted in India (DEN-302) that assessed safety and immunogenicity in 4–60 year-olds. The company said, “The study demonstrated that QDENGA was found to be tolerated, safe and immunogenic in healthy adults, adolescents and children. These clinical outcomes are further supported by real-world evidence generation and ongoing pharmacovigilance to deepen understanding of the vaccine’s safety and impact.”

Mahender Nayak, Takeda’s Head of Intercontinental Markets, said the latest seven-year data show continued protection against dengue infection and hospitalisation across all four serotypes, calling the result “an important milestone for communities and health systems.” He noted that since its 2022 launch QDENGA has been approved in 43 countries and more than 32 million doses have been distributed globally.

Peter Streibl, General Manager for the Southeast Asia and India Cluster, said dengue is a shared regional challenge that requires cross-border collaboration and pledged Takeda’s support for access to QDENGA where approved, alongside efforts to strengthen surveillance, awareness, vector control and community engagement. Goh Choo Beng, Medical Affairs Head for the cluster, added that all four dengue serotypes circulate in parts of India and that QDENGA is designed to protect regardless of prior exposure.

Original Source: https://www.thehindubusinessline.com/news/national/takedas-qdenga-approved-in-india-can-be-given-despite-pre-exposure-to-dengue/article71244817.ece
Category:
Tags:
Publish Date: 2026-07-20 16:41:00

Author

adminitfy

Follow Me
Other Articles
Tripura Opposition Demands Judicial Probe into DGP Dhankhar's Death
Previous

Tripura Opposition Demands Judicial Probe into DGP Dhankhar’s Death

Floods Cut Off Hospital: Tea Worker Delivers Baby in Sivasagar Factory
Next

Floods Cut Off Hospital: Tea Worker Delivers Baby in Sivasagar Factory

Search...

Recent Posts

  • Mumbai Crime Festival: Underworld Families’ Shocking Secrets
    by adminitfy
    November 21, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Mumbai Crime Festival: Underworld Families’ Shocking Secrets
  • CM Pays Last Respects as Manipur BJP MLA’s Mortal Remains Reach Imphal
  • Centre Deploys 25 More CAPF Companies Ahead of Tripura Civic Polls
  • Architecting the Human Interface: The Strategic Value of Work Environments
  • Assam: Nagaon Man Accused of ‘Love Jihad’ Duping Six Hindu Women
  • November 2026 (656)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.